STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 2860-2865

  Luo, Tuoping ^a,b   Masson, Kristina ^a   Jaffe, Jacob D ^a   Silkworth, Whitney ^a   Ross, Nathan T ^a,f   Scherer, Christina A ^a   Scholl, Claudia ^c   Fröhling, Stefan ^c   Carr, Steven A ^a   Stern, Andrew M ^a   Schreiber, Stuart L ^a,b,d   Golub, Todd R ^a,d,e  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRD 0188; BRD 0828; BRD 1045; BRD 1869; BRD 2998; BRD 3695; BRD 3752; BRD 3773; BRD 4220; BRD 4980; BRD 5749; BRD 5930; BRD 6818; BRD 7071; BRD 7446; BRD 7647; BRD 7657; BRD 7868; BRD 8899; BRD 9573; BRD 9949; FASUDIL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; PROTEIN MST4; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE 33; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEOMICS; STRUCTURE ACTIVITY RELATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOQUINOLINES; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SMALL MOLECULE LIBRARIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84857422433     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1120589109     Document Type: Article

References (24)

1. Friday BB, Adjei AA (2005) K-ras as a target for cancer therapy. Biochim Biophys Acta 1756:127-144. (Pubitemid 41773139)
2. Karnoub AE, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9:517-531. (Pubitemid 351881844)
3. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
4. Engelman JA, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356.
5. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278:1064-1068. (Pubitemid 27517876)
6. Barbie DA, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112.
7. Luo J, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848.
8. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823-837.
9. Scholl C, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834.
10. Kinter M, Sherman NE (2000) Protein Sequencing and Identification Using Tandem Mass Spectrometry (Wiley-Interscience, New York).
11. Jaffe JD, et al. (2008) Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics 7:1952-1962.
12. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. (Pubitemid 29278954)
13. Breitenlechner C, et al. (2003) Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 11:1595-1607. (Pubitemid 37510358)
14. Brauksiepe B, et al. (2008) The Serine / threonine kinase STK33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin. BMC Biochem 23:9-25.
15. Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31:438-448.
16. Karaman MW, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
17. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502.
18. Reichardt P, Reichardt A, Pink D (2011) Molecular targeted therapy of gastrointestinal stromal tumors. Curr Cancer Drug Tar 11:688-697.
19. Okamoto I, Mitsudomi T, Nakagawa K, Fukuoka M (2010) The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. Therapeutic Advances in Medical Oncology 2:301-307.
20. Flaherty KT, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl J Med 363:809-819.
21. Sharma SV, Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21:3214-3231. (Pubitemid 350277749)
22. Babij C, et al. (2011) STK33 kinase activity is non-essential in KRAS-dependent cancer cells. Cancer Res 71:5818-5826.
23. Prince JT, Ahn NG (2010) The case of the disappearing drug target. Mol Cell 37:455-456.
24. Hoshi N, et al. (2010) Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell 37:541-550.